Sign Up to like & get
recommendations!
0
Published in 2018 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2018.03.009
Abstract: AIMS We explored the risks associated with metformin plus sulfonylurea (MET + SU) or MET plus a dipeptidyl peptidase-4 inhibitor (MET + DPP4i) for hypoglycemia, cardiovascular disease (CVD) events and all-cause mortality in type 2 diabetes (T2D) patients with…
read more here.
Keywords:
events cause;
metformin combined;
cause mortality;
cvd events ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-90963-8
Abstract: KRAS mutations can cause metabolic reprogramming in ovarian cancer, leading to an increased metastatic capacity. This study investigated the metabolic reprogramming changes induced by KRAS mutations in ovarian cancer and the mechanism of action of…
read more here.
Keywords:
mutant ovarian;
metformin combined;
combined 839;
kras mutant ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032408
Abstract: Rationale: Familial adenomatous polyposis (FAP) is an autosomal dominant genetic disease, with a very high cancer rate. At present, endoscopic resection of polyps ≥ 1 cm is often chosen for patients with non-cancerous polyps who are unwilling to…
read more here.
Keywords:
combined endoscopic;
metformin combined;
patients familial;
endoscopic therapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Cancer Science"
DOI: 10.1111/cas.13849
Abstract: The success of targeted drug therapies for treating cancer patients has attracted broad attention both in the academic community and social society. However, rapidly developed acquired resistance is becoming a newly recognized major challenge to…
read more here.
Keywords:
application metformin;
metformin combined;
cancer;
targeted drugs ... See more keywords